GlyCLICK® in Action: uPAR-Directed ADC Case Study
GenovisWebinar, Video
We are excited to welcome Virginia Metrangolo from the Finsen Laboratory who will present the preclinical development of uPAR-directed ADCs. These are designed to overcome traditional barriers to clinical success by targeting both tumor and stromal compartments.
Key Learning Objectives
- Learn the principles behind antibody and target selection for ADC design
- Discover how GlyCLICK-based conjugation enables flexible and efficient antibody modification for versatile applications
- Gain insight into how integrated conjugation strategies can accelerate and de-risk preclinical ADC development
- Understand key considerations when translating antibody discovery into ADC constructs
Related Products
Related Applications
Supports high-quality immunofluorescence imaging with consistent signal intensity and reliable quantification through defined antibody labeling.
Site-specific ADC generation with defined DAR, preserving antigen binding and delivering potent, controlled cytotoxicity in target cells.
